Personalis’s liquid biopsy is part of a growing market for minimal residual disease assays, tests that look for any remaining cancer cells after the initial treatment. Tempus AI has been the commercial partner on this Personalis test since 2023. The post Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis appeared first on MedCity News .
Axiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX), followed by a co-listing on the Nasdaq—a strategy the company claims is the first U.S. biotech to use.
These three legal regimes are pulling in different directions, and the developers that navigate them well will be the ones that plan for all three from the start. The post The AI Tension in Healthcare: Patent Strategy, FDA Reality, and HIPAA Constraints appeared first on MedCity News .
Rural Health Transformation Program funding gives states broad flexibility and may help address longstanding access gaps. The post For Millions in Rural America, Medicine Is Still Far Away appeared first on MedCity News .
Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff - Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions
A team of veteran scientists from elite institutions has come together to form a new center dedicated to the crafting of personalized genetic medicines, adding to the growing list of similar efforts in the wake of Baby KJ’s groundbreaking custom CRISPR treatment.
The supply of the circuit boards needed to fix the devices is significantly constrained, preventing the company from immediately correcting all affected ventilators.
Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercomputer for drug R&D, according to the announcement.
A new PwC report says the women’s oncology market could reach $110 billion by 2030, though funding and care gaps remain. The post Women’s Oncology Market Could Reach $110B in 2030, but Gaps Remain appeared first on MedCity News .
Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic peptide designed for formulation as an oral drug. The post Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs appeared first on MedCity News .
Latigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps. The post Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges appeared first on MedCity News .
Here’s what healthcare entities should know about the maturing landscape, what to actually be concerned about, and the next stage of healthcare data evolution as we know it. The post Are We Entering an Interoperability Trust Recession? appeared first on MedCity News .
Geopolitical uncertainty has continued to “chill” IPO sentiment among British biotechs, an industry leader has told Fierce, even as the sector saw second-quarter venture capital funding reach a five-year high.
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
Juno Bio’s funding was supported by Ada Ventures, Artesian, Entrepreneur First and Illumina Accelerator. The post Juno Bio Raises $3.8M to Support Vaginal Health appeared first on MedCity News .
Despite an unexpected slowdown in U.S. procedure growth, system placements remained healthy, and the surgical robotics company maintained its 2026 forecast for worldwide da Vinci robot procedures.